Prostate cancer follow-up costs in Germany from 2000 to 2015

Michaeli, Thomas; Michaeli, Daniel Tobias

doi:10.1007/s11764-021-01006-w

Cited by 7 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer survivors under hormone treatment require a more intensive follow-up, when compared with breast or colorectal cancer survivors. A German study reported that the estimated 10-year follow-up costs for prostate cancer survivors has increased, in particular if hormone therapy is prescribed, from EUR 1361 in 2000 to EUR1777 in 2015, after accounting for inflation (Michaeli and Michaeli 2021 ). In addition, a greater portion of these increased costs were borne by survivors rather than insurance providers.…”

Section: Discussionmentioning

confidence: 99%

Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study

Thong

Doege

Weißer

et al. 2021

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Limited research suggests that cancer survivors have problems with insurance. Our study aimed to gain insight into the proportion of very long-term (14–24 years post-diagnosis) survivors of breast, colorectal, and prostate cancers who had problems with health (HI) and life (LI) insurance. Methods We used data from CAESAR (CAncEr Survivorship—A multi-Regional population-based study). Participants completed questions on change in insurance providers since cancer diagnosis, problems with requesting (additional) HI or LI, and how potential problems were resolved. We conducted logistic regression to determine factors associated with change in statutory HI. Results Of the 2714 respondents, 174 (6%) reported having changed HI providers. Most switched between different statutory HI providers (86%), 9% from statutory to private, and 5% from private to statutory. Respondents who changed statutory HI providers were more likely to be prostate cancer survivors (OR 2.79, 95% CI 1.01–7.68) while being ≥ 65 years at time of diagnosis (OR 0.58, 95% CI 0.35–0.96) and having ≥ 2 comorbid conditions (OR 0.61, 95% CI 0.40–0.92) were associated with reduced odds for change. Problems in changing HI were minimal and were resolved with additional contribution. Of the 310 respondents who tried to get LI, 25 respondents reported having difficulties, of whom the majority had their request rejected. Conclusion Most cancer survivors did not change their HI nor tried to buy LI after cancer diagnosis. Problems with changing statutory HI were generally resolved with additional contribution while the main problem encountered when buying LI was rejection of request.

show abstract

Section: Discussionmentioning

confidence: 99%

Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study

Thong

Doege

Weißer

et al. 2021

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…An established costing methodology was employed to calculate the socio‐economic burden of RCC survivorship in Germany (Michaeli et al, 2021, 2022; Michaeli & Michaeli, 2022). In accordance with the EAU guidelines' risk‐stratification, we estimated costs across three distinct patient groups: low‐, medium‐, and high‐risk RCC.…”

Section: Methodsmentioning

confidence: 99%

Socio‐economic burden of disease: Survivorship costs for renal cell carcinoma

Michaeli

Boch

et al. 2022

European J Cancer Care

Self Cite

View full text Add to dashboard Cite

Objective The objective of this study is to assess the risk‐stratified 10‐year socio‐economic burden of renal cell carcinoma (RCC) follow‐up costs after initial treatment in Germany from 2000 to 2020. Methods A micro‐costing method considering direct and indirect medical expenditure associated with follow‐up procedures was employed to calculate survivorship costs per patient. The frequencies of physician–patient visits, examinations and diagnostic tests were extracted from guidelines, whilst expenses were sourced from literature and official scales of tariffs. Societal costs were calculated based on three perspectives: patients, providers and insurers. Results Mean societal 10‐year follow‐up costs per patient amounted to EUR 3,377 (95%CI: 2,969–3,791) for low‐risk, EUR 3,367 (95%CI: 3,003–3,692) for medium‐risk and EUR 4,299 (95%CI: 3,807–4,755) for high‐risk RCC in 2020. Spending increased by +32% from 2000 to 2020 for low‐risk RCC, whilst medium‐and high‐risk RCC expenditure was cut by −39% and −22%, respectively. Patients shouldered 27%, providers 43% and insurers 35% of costs in 2020. Resources were consumed by medical imaging (52%), physician‐patient consultations (31%), travel expenses (17%) and blood tests (1%). Conclusion Results highlight the economic burden cancer survivorship poses for society. Cancer survivors require individualised, evidence‐based and insurance‐covered follow‐up schedules to permit the early detection of side‐effects, metastasis and secondary malignancies.

show abstract

“…The German Federal Joint Committee declines the financial coverage of such testing by health insurance funds. Available validated instruments should accompany the baseline prostate-specific antigen to optimize detection of clinically significant prostate cancer [4].…”

Section: Methodsmentioning

confidence: 99%

Robot-Assisted Radical Prostatectomy With Da Vinci Xi: Our Initial Experience

Anakievski¹,

Marinov²,

Gocheva³

et al. 2022

JofIMAB

View full text Add to dashboard Cite

During the recent years, prostate cancer becomes a major socio-medical challenge worldwide, as well as in Bulgaria, because of its rising importance and unfavorable impact on human health. Recently we are facing significant theoretical and practical advances in the field of minimally invasive prostate cancer surgery. The last two decades witness a dramatic change in the surgical treatment of most urological diseases with the adventage of a robotic surgical platform. In fact, surgical treatment of prostate cancer has undergone most significant change, thus almost every case nowadays is performed with a robot. The present abstract indicates our initial experience with the use of da Vinci Xi-system in prostate cancer surgery. Materials and methods: 137 robot-assisted radical prostatectomies have been performed in patients with prostate cancer for the period 1 February 2020 / 1 May 2021 in our clinic. Results: The average operative time for the performed operations with minimal blood loss was 160 minutes. Blood transfusion was performed to two patients, whereas no conversion of operations was required in other patients. About half of the patients underwent extended pelvic lymph node dissection due to the high risk for them. Conclusion: Robot assisted radical prostatectomy (RARP) is shown to be an easily performed laparoscopic technique and best practice, compared to the standard open procedure. When analyzing the open approach, certain preliminary studies indicate that robotic prostatectomy has similar outcomes in short-term oncologic control, continence and potency. Initial long-term quality-of-life outcomes have demonstrated priority results for robotic radical prostatectomy, compared to open radical prostatectomy.

show abstract

Prostate cancer follow-up costs in Germany from 2000 to 2015

Cited by 7 publications

References 38 publications

Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study

Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study

Socio‐economic burden of disease: Survivorship costs for renal cell carcinoma

Robot-Assisted Radical Prostatectomy With Da Vinci Xi: Our Initial Experience

Contact Info

Product

Resources

About